Benzinga | Mar 29, 2021 07:09AM EDT

Amarin Highlights Inclusion Of Icosapent Ethyl In Multiple Journals

Amarin Corporation plc (NASDAQ:AMRN) today announced that the Canadian Cardiovascular Society (CCS) and the Egyptian Heart Journal (EHJ) (the official journal of the Egyptian Cardiovascular Society) have included icosapent ethyl in the 2021 Canadian Cardiovascular Society Guidelines1 and in the Egyptian Heart Journal's Practical Guidance in Lipid Management2 respectively, for the reduction of cardiovascular risk. These recommendations increase to 15 the number of global organizations or medical societies that recommend icosapent ethyl for cardiovascular risk reduction following its previously reported favorable outcomes study results. These independent recommendations support the company's view that this important drug, marketed in the United States as VASCEPA(r), is rapidly becoming a new standard of care for the treatment of appropriate high-risk patients.